For BPC-157 to move from experimental to evidence-based, the research community would need: Phase I (Safety) 50-100 healthy volunteers Multiple dose levels Comprehensive pharmacokinetic profiling Adverse event monitoring for 4-8 weeks minimum Phase II (Efficacy Signals) 100-300 patients with specific conditions Randomized, placebo-controlled design Validated outcome measures 3-6 month follow-up minimum Phase III (Confirmatory) 500-3000 patients Multi-site trials Long-term safety monitoring Comparison to existing treatments Currently, were stuck before Phase I even completes
Supply chain will be the real differentiator: Peptide based injectables and oral forms are complex to manufacture at scale
Reviews reflect this intentional gradation, with some patients reporting rapid tolerance and others needing extended low-dose periods
And while some embrace their grays, others turn to the trusted antidote, hair dye, to hide it
Chronic inflammation then activates hepatic stellate cells through transforming growth factor beta (TGF-) and platelet-derived growth factor (PDGF) signalling, driving extracellular matrix deposition and fibrogenesis
